Pardes-Hanna, Israel, November 19, 2019 – RedDress®, an Israel-based company with the goal of developing more effective, natural and economically viable treatment for chronic wounds, advanced to the final round of the 2019 "Chuangxiang China" Anhui Innovation & Entrepreneurship Competition (Tel Aviv Division), hosted in Tel Aviv, Israel. According to Xinhua, a total of 110 Israeli hi-tech startups applied for the competition; 12 of which – primarily in the medical and healthcare sector – qualified to participate in the second round of the competition, including RedDress. The second round of the competition, which was completed in September 2019, consisted of presentations and meetings. RedDress was among the three Israeli startups selected to advance forward to the third – and final – round of the competition.

The final round of the "Chuangxiang China" Anhui Innovation & Entrepreneurship Competition will be held in November 2019 in Hefei, the capital of east China’s Anhui Province. To learn more visit:

About RedDress RedDress is proud to introduce ActiGraft, the world's first whole-blood clot tissue, point-of-care wound care solution that recreates the natural wound healing process of the body. ActiGraft’s intended use allows it to be used on all types of chronic wounds including diabetic foot, pressure and venous ulcers. Designed with nurses in mind, ActiGraft is easy-to-use, cost effective and efficient. RedDress is dedicated to developing revolutionary, biologic advanced wound care products, based on a patented technology to recreate the natural process of the body to heal wounds.